Westdeutsches Tumorzentrum Essen

Featured in: Favicon

Articles

Phase 3 CLEAR Study in Patients With Advanced Renal Cell Carcinoma: Outcomes in Subgroups for the Lenvatinib-Plus-Pembrolizumab and Sunitinib Arms

May 15, 2023 | frontiersin.org | Westdeutsches Tumorzentrum Essen |Universitätsklinikum Essen |Sun Young |Woodcliff Lake

Phase 3 CLEAR Study in Patients With Advanced Renal Cell Carcinoma: Outcomes in Subgroups for the Lenvatinib-Plus-Pembrolizumab and Sunitinib Arms Viktor Grünwald1*, Thomas Powles2, Masatoshi Eto3, Evgeny Kopyltsov4, Sun Young Rha5, Camillo Porta6, Robert Motzer7, Thomas E. Hutson8, María José Méndez-Vidal9, Sung-Hoo Hong10, Eric Winquist11, Jeffrey C. Goh12, Pablo Maroto13, Tomas Buchler14, Toshio Takagi15, Joseph E. Burgents16, Rodolfo Perini16, Cixin He17, Chinyere E.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.